A Phase 1 interventional study of BI 6727 and BIBF 1120 in Neoplasms, sponsored by Boehringer Ingelheim. Completed at 2 sites in Italy. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2018-07-30.
Sponsored by Boehringer Ingelheim · Phase 1, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
The primary objective of the current study is to investigate the Maximum Tolerated Dose (MTD) in terms of safety and tolerability of BI 6727 in combination with fixed dose BIBF 1120, in patients with advanced or metastatic solid tumours.
10,826 studies on the registry are indexed under Neoplasms; 2,322 are open to participants now.
This study's enrollment of 30 is below the median of 60 across 7,707 interventional studies indexed under Neoplasms.
Browse Neoplasms studies →Boehringer Ingelheim is the lead sponsor of 2,305 studies on the registry; 62 are open to participants now.
Of its 169 completed or terminated interventional studies of FDA-regulated products, 123 (73%) have results posted.
Counted across the registry records on this site, refreshed daily.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Metastases
Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Informed consent
Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.
You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
CTCAE grade
The US National Cancer Institute’s scale of how severe an adverse event is — any unwanted medical event during a study, such as a symptom, an illness or an abnormal test result, whether or not a treatment caused it. Whether it did is judged separately.
“Side effects of earlier treatment resolved to grade 1 or less” means they have settled to mild or gone.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Hypersensitivity
An allergy, or another reaction of the immune system, to a substance. “Hypersensitivity to the study drug” means a known allergic reaction to it — not every side effect a medicine can have.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Excipients
The other ingredients in a medicine besides the active drug, such as fillers, colors or preservatives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Investigational drug or device
A drug or device being studied in a clinical trial.
It may be new, or already approved and being studied for another use, dose or form. Criteria often leave out people who took part in another study of one within a recent period, commonly 30 days or five half-lives.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Corticosteroids (steroids)
Anti-inflammatory medicines such as prednisone, prednisolone and dexamethasone — not the anabolic steroids used for muscle.
Studies differ in what they allow: check which steroid medicines, routes (tablets, injections, creams, inhalers, eye drops) and doses this study accepts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
HIV
The human immunodeficiency virus, which weakens the immune system.
Many studies now accept people whose HIV is controlled on treatment, judged by the viral load and the CD4 count. Check the limits this study sets.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Cancer (malignancy)
Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.
Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Leptomeningeal disease
Cancer that has spread to the leptomeninges, the thin layers covering the brain and spinal cord, and the fluid between them. It is not the same as brain metastases.
Criteria often treat it separately, and many studies leave it out even where treated brain metastases are allowed.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Clinically significant
Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Absolute neutrophil count (ANC)
The number of neutrophils, white blood cells that help fight infection, in a given amount of blood. Too few raises the risk of infection.
It is a count, not a percentage of the white cells. Limits are written in units that mean the same: ≥ 1.5 × 10⁹/L is ≥ 1,500 per mm³ (µL). Each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Platelets
Blood cells that help blood clot. Too few raises the risk of bleeding and bruising. A usual adult range is about 150–400 × 10⁹/L (150,000–400,000 per µL); each lab has its own reference range.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Bilirubin
A yellow substance made when red blood cells are broken down, which the liver clears. A high level can mean a problem with the liver or the bile ducts.
Criteria often allow more for people with Gilbert’s syndrome, a harmless inherited condition that raises bilirubin.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ULN (upper limit of normal)
The top of the normal range for a blood test, as set by the laboratory that runs it. Each lab prints its own range next to your result.
“≤ 2.5 × ULN” means the result can be up to two and a half times that top value.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
ALT and AST (liver enzymes)
Two enzymes measured in a routine blood test of the liver. Higher levels can mean the liver is under strain or damaged. SGPT and SGOT are older names for ALT and AST.
Criteria usually give a limit as a multiple of the upper limit of normal (ULN), often higher when cancer has spread to the liver.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
QT and QTc
On an ECG, the QT interval is the time the heart’s lower chambers take to activate electrically and recover in each beat. QTc is that time adjusted for heart rate (QTcF by Fridericia’s formula, QTcB by Bazett’s). Some medicines lengthen it, and a long QTc can raise the risk of a dangerous heart rhythm.
The study may name a correction formula and a limit in milliseconds, often around 450–480.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Finding Maximum Tolerated Dose of BI 6727 in combination with BIBF 1120
Drug: BI 6727 · Drug: BIBF 1120
Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD).
DLT was defined as: 1. Drug-related CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia
Time frame: 28 days
Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib
The MTD was determined using a 3+3 design with de-escalation. The MTD was defined as the highest dose level at which maximal 1 out of 6 patients experienced DLT in the first course of the escalation nd de-escalation phase. However, all DLT's occurring in the trial were considered for selection of the recommended dose for further development.
Time frame: 28 days
Number of Participants With Drug Related Adverse Events
Number of participants with investigator-defined drug related adverse events.
Time frame: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
Number of Participants With Dose Limiting Toxicities
Number of participants with dose limiting toxicities (DLTs). DLT was defined as: 1. Drug-related CTCAE grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia
Time frame: From first study drug administration until 28 days after the last administration of any study medication, up to 485 days
Cmax of Volasertib
Maximum measured concentration (Cmax) in plasma of Volasertib in Cycle 1.
Time frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
CL of Volasertib
Total plasma Clearance (CL) of Volasertib in Cycle 1.
Time frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
Vss of Volasertib
Volume of distribution at steady state (Vss) of Volasertib in Cycle 1.
Time frame: 0:05 h before start of Volasertib infusion and 1:00, 2:00, 3:00, 4:00, 8:00 and 24 h after start of Volasertib infusion
Cmax of Nintedanib
Maximum measured concentration (Cmax) of Nintedanib in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.
Time frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
AUC(0-6h) of Nintedanib
Area under the concentration-time curve (AUC) of Nintedanib over the time interval 0 to 6 hours in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.
Time frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
Tmax of Nintedanib
Time from dosing to the maximum measured concentration, Cmax, of Nintedanib (tmax) in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.
Time frame: 5 min before Nintedanib administration in the morning and 1:00, 2:00, 3:00, 4:00, 6:00 h after administration on Day 9
Number of Patients With Best Overall Response
Best overall response based on response evaluation criteria in solid tumors (RECIST) version 1.1. Best overall response is defined as the best overall response (complete response, partial response, stable disease, progressive disease or not evaluable) since the start of treatment.
Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Number of Patients With Objective Response (OR)
Objective tumor response based on response evaluation criteria in solid tumors (RECIST) version 1.1. OR is defined as complete response (CR) or partial response (PR) as best response throughout the study.
Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Number of Patients With Disease Control
Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Disease control is defined as complete response (CR), partial response (PR) or stable disease (SD) as best response throughout the study.
Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Duration of Disease Control
Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Patients who had a best overall tumour response of complete response (CR), partial response (PR) or stable disease (SD) were assessed to show disease control.
Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
Progression Free Survival (PFS)
PFS is defined as the time from start of treatment with study medication to tumour progression or death whichever occurs first. Tumour response was to be documented using appropriate techniques such as magnetic resonance imaging (MRI) or computer tomography (CT).
Time frame: Tumor assessment was performed at screening and every 2nd course until earliest time of progression, death or end of treatment.
An uncontrolled, open-label, dose escalation study in cohorts of patients following the '3+3 design with de-escalation'. After entering the study, cohorts of patients were sequentially allocated to the dose levels.
| Milestone | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Started | 3 | 4 | 13 | 8 | 2 |
| Completed | 0 | 0 | 0 | 0 | 0 |
| Not completed | 3 | 4 | 13 | 8 | 2 |
| Withdrew: Progressive disease | 2 | 3 | 11 | 7 | 1 |
| Withdrew: Dose-limiting toxicity | 0 | 0 | 0 | 0 | 1 |
| Withdrew: Withdrawal by subject | 0 | 1 | 1 | 1 | 0 |
| Withdrew: Other not stated above | 1 | 0 | 1 | 0 | 0 |
DLT was defined as: 1. Drug-related CTCAE (Common Terminology Criteria for Adverse Events) grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia
| participants | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities (DLTs) in the First Cycle for the Determination of the Maximum Tolerated Dose (MTD). | 0 | 0 | 3 | 2 | 2 |
Number of participants with investigator-defined drug related adverse events.
| participants | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Number of Participants With Drug Related Adverse Events | 3 | 3 | 12 | 7 | 2 |
Number of participants with dose limiting toxicities (DLTs). DLT was defined as: 1. Drug-related CTCAE grade 3 or 4 non-haematological toxicity (except untreated vomiting, untreated nausea, or untreated diarrhoea) or 2. Drug-related CTCAE grade 4 neutropenia for 7 or more days and/or complicated by infection or 3. CTCAE grade 4 thrombocytopenia
| participants | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Number of Participants With Dose Limiting Toxicities | 0 | 1 | 6 | 2 | 2 |
Maximum measured concentration (Cmax) in plasma of Volasertib in Cycle 1.
| ng/mL | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Cmax of Volasertib | 164 ± 77.6 | 409 ± 23.3 | 532 ± 33.3 | 534 ± 25.5 | 1210 ± 54.1 |
Total plasma Clearance (CL) of Volasertib in Cycle 1.
| mL/min | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| CL of Volasertib | 720 ± 19.30 | 685 ± 4.22 | 792 ± 34.2 | 849 ± 29.3 | 589 ± 18.3 |
Volume of distribution at steady state (Vss) of Volasertib in Cycle 1.
| L | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Vss of Volasertib | 5710 ± 39.9 | 5590 ± 6.53 | 5010 ± 34.7 | 6080 ± 21.2 | 2710 ± 87.3 |
Maximum measured concentration (Cmax) of Nintedanib in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.
| ng/mL | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|
| Cmax of Nintedanib | 22.5 ± 58.0 | 30.2 ± 66.2 | 36.7 ± 53.3 | 34.2 ± 53.8 |
Area under the concentration-time curve (AUC) of Nintedanib over the time interval 0 to 6 hours in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.
| ng*h/mL | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|
| AUC(0-6h) of Nintedanib | 69.5 ± 29.9 | 104.0 ± 59.4 | 135.0 ± 48.8 | 121.0 ± 51.0 |
Time from dosing to the maximum measured concentration, Cmax, of Nintedanib (tmax) in Cycle 1. 400 mg Volasertib + 200 mg Nintedanib group is not displayed due to data only being available for one patient.
| h | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|
| Tmax of Nintedanib | 3.00 (3.00 to 3.00) | 1.88 (1.00 to 2.75) | 2.42 (1.00 to 3.00) | 2.00 (1.00 to 6.00) |
Best overall response based on response evaluation criteria in solid tumors (RECIST) version 1.1. Best overall response is defined as the best overall response (complete response, partial response, stable disease, progressive disease or not evaluable) since the start of treatment.
| participants | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Complete Response | 0 | 0 | 1 | 0 | 0 |
| Partial Response | 0 | 0 | 1 | 0 | 0 |
| Stable Disease | 2 | 2 | 7 | 4 | 1 |
| Progressive Disease | 1 | 2 | 3 | 3 | 0 |
| Not Evaluable | 0 | 0 | 0 | 0 | 0 |
| Missing | 0 | 0 | 1 | 1 | 1 |
Objective tumor response based on response evaluation criteria in solid tumors (RECIST) version 1.1. OR is defined as complete response (CR) or partial response (PR) as best response throughout the study.
| participants | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Objective Response (OR) | 0 | 0 | 2 | 0 | 0 |
| Missing | 0 | 0 | 1 | 1 | 1 |
The MTD was determined using a 3+3 design with de-escalation. The MTD was defined as the highest dose level at which maximal 1 out of 6 patients experienced DLT in the first course of the escalation nd de-escalation phase. However, all DLT's occurring in the trial were considered for selection of the recommended dose for further development.
| mg | Volasertib in Combination With Nintedanib |
|---|---|
| Maximum Tolerated Dose (MTD) of Volasertib in Combination With Nintedanib | 300 |
Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Disease control is defined as complete response (CR), partial response (PR) or stable disease (SD) as best response throughout the study.
| participants | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Number of Patients With Disease Control | 2 | 2 | 9 | 4 | 1 |
Disease control based on response evaluation criteria in solid tumors (RECIST) version 1.1. Patients who had a best overall tumour response of complete response (CR), partial response (PR) or stable disease (SD) were assessed to show disease control.
| days | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib | Total Patients |
|---|---|---|---|---|---|---|
| Duration of Disease Control | 163.0 (114.0 to 212.0) | 348.0 (184.0 to 512.0) | 141.0 (74.0 to 447.0) | 215.0 (94.0 to 394.0) | 56.0 (56.0 to 56.0) | 161.5 (56.0 to 512.0) |
PFS is defined as the time from start of treatment with study medication to tumour progression or death whichever occurs first. Tumour response was to be documented using appropriate techniques such as magnetic resonance imaging (MRI) or computer tomography (CT).
| days | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib | Total Patients |
|---|---|---|---|---|---|---|
| Progression Free Survival (PFS) | 114.0 (45.0 to 212.0) | 116.0 (35.0 to 512.0) | 99.0 (30.0 to 447.0) | 72.5 (8.0 to 394.0) | 83.0 (56.0 to 110.0) | 96.5 (8.0 to 512.0) |
Collected over All adverse events (AEs) that occurred during therapy with the study medication, or within 28 days after the last administration of any study medication, up to 485 days. Non-serious events are listed at a 5% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 100 mg Volasertib + 200 mg Nintedanib | — | 0/3 (0%) | 3/3 (100%) |
| 200 mg Volasertib + 200 mg Nintedanib | — | 0/4 (0%) | 4/4 (100%) |
| 300 mg Volasertib + 200 mg Nintedanib | — | 5/13 (38.5%) | 13/13 (100%) |
| 350 mg Volasertib + 200 mg Nintedanib | — | 2/8 (25%) | 8/8 (100%) |
| 400 mg Volasertib + 200 mg Nintedanib | — | 1/2 (50%) | 2/2 (100%) |
| Event | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| Febrile neutropeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/13 | 0/8 | 1/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/13 | 0/8 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 0/13 | 0/8 | 1/2 |
| Intestinal obstructionGastrointestinal disorders | 0/3 | 0/4 | 0/13 | 1/8 | 0/2 |
| Malignant neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/4 | 0/13 | 1/8 | 0/2 |
| PyrexiaGeneral disorders | 0/3 | 0/4 | 1/13 | 0/8 | 0/2 |
| Metastases to meningesNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/4 | 1/13 | 0/8 | 0/2 |
| Neoplasm progressionNeoplasms benign, malignant and unspecified (incl cysts and polyps) | 0/3 | 0/4 | 1/13 | 0/8 | 0/2 |
| Bladder obstructionRenal and urinary disorders | 0/3 | 0/4 | 1/13 | 0/8 | 0/2 |
| HaematuriaRenal and urinary disorders | 0/3 | 0/4 | 1/13 | 0/8 | 0/2 |
| Event | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib |
|---|---|---|---|---|---|
| AnaemiaBlood and lymphatic system disorders | 0/3 | 0/4 | 4/13 | 2/8 | 2/2 |
| LeukopeniaBlood and lymphatic system disorders | 0/3 | 0/4 | 4/13 | 1/8 | 2/2 |
| NauseaGastrointestinal disorders | 3/3 | 2/4 | 4/13 | 6/8 | 1/2 |
| VomitingGastrointestinal disorders | 1/3 | 2/4 | 6/13 | 3/8 | 2/2 |
| AstheniaGeneral disorders | 2/3 | 2/4 | 8/13 | 5/8 | 2/2 |
| Chest painGeneral disorders | 3/3 | 1/4 | 1/13 | 0/8 | 0/2 |
| Abdominal pain upperGastrointestinal disorders | 1/3 | 3/4 | 1/13 | 2/8 | 1/2 |
| NeutropeniaBlood and lymphatic system disorders | 0/3 | 1/4 | 9/13 | 4/8 | 1/2 |
| DiarrhoeaGastrointestinal disorders | 2/3 | 1/4 | 8/13 | 4/8 | 1/2 |
| ThrombocytopeniaBlood and lymphatic system disorders | 0/3 | 1/4 | 8/13 | 5/8 | 1/2 |
Treated Set - All patients who received ≥1 dose of study medication were included in the treated set.
| Age, Continuous(years) | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib | Total |
|---|---|---|---|---|---|---|
| Mean | 53.0 ± 9.2 | 60.0 ± 7.1 | 57.5 ± 8.8 | 53.1 ± 12.9 | 59.0 ± 5.7 | 56.3 ± 9.6 |
| Sex: Female, Male(Participants) | 100 mg Volasertib + 200 mg Nintedanib | 200 mg Volasertib + 200 mg Nintedanib | 300 mg Volasertib + 200 mg Nintedanib | 350 mg Volasertib + 200 mg Nintedanib | 400 mg Volasertib + 200 mg Nintedanib | Total |
|---|---|---|---|---|---|---|
| Female | 1 | 1 | 7 | 2 | 1 | 12 |
| Male | 2 | 3 | 6 | 6 | 1 | 18 |
The record gives a start of Dec 2009, a primary completion of Feb 2013 and a completion of Feb 2013. It does not say whether these dates are actual or estimated.
Results were first posted in Jul 2018, 5 years 5 months after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is completed, as verified in Oct 2017. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drugs tested here: BI 6727 · Nintedanib